Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | MMP2 | P08253 | 5/20 | 0.62 |
| ▸ | MMP3 | P08254 | 2/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182038 | 0.90 | BMP1 (0.81) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7647602 | 0.90 | BMP1 (0.81) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6428262 | 0.89 | BMP1 (0.78) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27567224 | 0.89 | BMP1 (0.78) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6429734 | 0.87 | BMP1 (0.82) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5411976 | 0.86 | BMP1 (0.65) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6430549 | 0.86 | BMP1 (0.73) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6179694 | 0.85 | BMP1 (0.64) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27586640 | 0.84 | BMP1 (0.85) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6428677 | 0.84 | BMP1 (0.85) | BMP1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-6716861-B2 | HETEROCYCLIC 1,2,4-OXADIAZOLE OR OXAZOLE RING CONTAINING PROPANOHYDROXAMIC ACIDS USEFUL AS ANTISCARRING AGENT | PFIZER, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1343771-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | PFIZER, INC | 2002-10-17 | — | — | US | disclosed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | ALPI, TIMP3, MMP1 | BMP1 376/4885PDE4A 1458/4885PDE4B 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.